Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Recent developments of pharmacogenomics in the treatment of colorectal cancers].

Annales pharmaceutiques francaises - 1 Jul 2010

Astier A

Abstract excerpt

Colorectal cancer (CCR), which is one of the most common causes of cancer, has benefited from the major advances in the understanding of the intracellular signaling pathways implicated in the initiation, growing and local and metastasis dissemination of tumor, which have occurred during the 20 pa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Biotransformation
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Drug Screening Assays, Antitumor

Share to Irinotecan

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Identifiers

PMID: 20637356
DOI: 10.1016/j.pharma.2010.04.001

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20637356-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Recent developments of pharmacogenomics in the treatment of colorectal cancers].PMID 20637356Read ↗

Pharmacogenomics in colorectal cancer: The first step for individualized-therapySemantic proximity Read ↗

[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].Semantic proximity Read ↗

[Pharmacogenomics and chemotherapy].Semantic proximity Read ↗

Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).Semantic proximity Read ↗

FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.Semantic proximity Read ↗

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.Semantic proximity Read ↗

[Pharmacogenetics of anti-cancer drugs].Semantic proximity Read ↗

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.Semantic proximity Read ↗

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphismsSemantic proximity Read ↗

Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them.Semantic proximity Read ↗

Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines.Semantic proximity Read ↗

Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.